Godavari Drugs (GODAVARI) Share Price Falls 10.45% Today to Rs 106.60
- September 15, 2026
- Posted by: Harsh Piplani
- Category: News
Godavari Drugs Share Price fell to Rs 106.60 today, down 10.45%, taking the company’s market capitalisation to Rs 129.92 crore. The Micro Cap pharmaceutical stock is drawing attention after a sharp same-day decline from the previous close of Rs 119.04. Based on the supplied data, the price event is clear, while no company-specific catalyst is established here.
Godavari Drugs Share Price Today also stands out because the stock opened at Rs 115.75, touched the same Rs 115.75 as the day’s high, and then slipped to a low of Rs 105.65 before trading near that lower band. Turnover was Rs 0.03 crore, showing a small-value session in absolute terms. For investors tracking Godavari Drugs Stock News, the key questions now are whether this move changes the technical setup, how the valuation compares with the pharmaceuticals benchmark, and whether the company’s profitability metrics support ongoing market attention. Univest data shows a mixed picture rather than a one-sided one.
Godavari Drugs (GODAVARI) Share Price Today: Price Action Analysis
| Metric | Value |
|---|---|
| Current Price | Rs 106.6 |
| Previous Close | Rs 119.04 |
| Today's Move | -Rs 12.44 (-10.45%) |
| Open | Rs 115.75 |
| High | Rs 115.75 |
| Low | Rs 105.65 |
| Turnover | Rs 0.03 crore |
| Market Capitalisation | Rs 129.92 crore |
| Market Cap Category | Micro Cap |
Godavari Drugs Share Price Today reflects a sharp intraday reset, with the stock opening weak versus the previous close and then extending losses through the session. The combination of an open at Rs 115.75, a day high also at Rs 115.75, and a low of Rs 105.65 suggests early selling pressure that prevented any meaningful recovery attempt.
The stock closed the previous session at Rs 119.04 and is now at Rs 106.60, a fall of Rs 12.44 or 10.45% in today’s decline. That places the current price close to the day’s low, which is usually notable because it shows weakness persisted late into the session rather than reversing quickly. For a Micro Cap company with a market cap of Rs 129.92 crore, such moves can attract outsized attention in Share Market Today discussions even when turnover is only Rs 0.03 crore.
For readers following Godavari Drugs Share Price Live and Godavari Drugs Share Price Update trends, the factual takeaway is simple: the stock moved lower from the open, never exceeded that opening level, and remained under pressure into the current print. That price action matters because it frames how investors read the stock’s broader valuation and operating efficiency metrics on Univest.
Godavari Drugs (GODAVARI) Fundamental Analysis
| Metric | Value |
|---|---|
| Market Capitalisation | Rs 129.92 crore |
| P/E Ratio | 31.26x |
| P/B Ratio | 1.65x |
| ROE | 10.64% |
| ROCE | 10.13% |
| EPS | Rs 3.81 |
| Book Value Per Share | Rs 72.07 |
| Dividend Yield | 0% |
Godavari Drugs Fundamental Analysis shows a business that is modestly profitable by sector standards, but not obviously expensive when set against the broader pharmaceuticals benchmark. At a market cap of Rs 129.92 crore and a P/E ratio of 31.26, the stock is valued slightly below the same-industry median P/E of 32.72 and well below the industry average of 49.15.
The P/B ratio stands at 1.65, which is also below the industry median of 3.05 and average of 4.37. That matters because book value per share is Rs 72.07, giving investors a balance-sheet reference point behind the current stock price. EPS is Rs 3.81, which explains the earnings base supporting the present valuation multiple. Dividend yield is 0, indicating there is no current yield support in the supplied figures.
On profitability, ROE is 10.64% and ROCE is 10.13%. Those numbers are close to the industry ROE average of 10.54%, but below the industry ROE median of 11.69%, ROCE median of 13.24% and ROCE average of 13.09%. In plain terms, the valuation is not stretched against the sector snapshot, but profitability is also not standing out as a clear strength. That balance is central to any Godavari Drugs Stock Analysis on Univest.
Sector and Industry Context
| Metric | Value |
|---|---|
| Sector | Healthcare |
| Industry | Pharmaceuticals & Drugs |
| Benchmark Scope | same industry |
| Company P/E Ratio | 31.26x |
| Benchmark Median P/E | 32.72x |
| Benchmark Average P/E | 49.15x |
| Benchmark P/E Range | 3.34x to 693.7x |
| Company P/B Ratio | 1.65x |
| Benchmark Median P/B | 3.05x |
| Benchmark Average P/B | 4.37x |
| Company ROE | 10.64% |
| Benchmark Median ROE | 11.69% |
| Benchmark Average ROE | 10.54% |
| Company ROCE | 10.13% |
| Benchmark Median ROCE | 13.24% |
| Benchmark Average ROCE | 13.09% |
| Company Market Capitalisation | Rs 129.92 crore |
| Benchmark Median Market Cap | Rs 704.59 crore |
| Benchmark Average Market Cap | Rs 13,873.11 crore |
Godavari Drugs operates in Healthcare within the Pharmaceuticals & Drugs industry, and the sector snapshot offers useful context for today’s move. Across the same industry benchmark of 204 companies, valuation and profitability vary widely, so the stock’s current numbers need to be read relative to that broader distribution rather than in isolation.
The company P/E of 31.26 sits below the industry median of 32.72 and well below the average of 49.15. The benchmark range is wide, from 3.34 to 693.7 across 169 companies with P/E data, which shows how dispersed sector valuations are. On P/B, Godavari Drugs is at 1.65, lower than the median of 3.05 and average of 4.37 across 203 companies. That can point to a less demanding valuation multiple versus much of the listed pharmaceuticals pack.
Profitability, however, is more mixed. Company ROE of 10.64% is below the median 11.69% but fractionally above the average 10.54%. ROCE at 10.13% is below both the median of 13.24% and average of 13.09%. Size is another differentiator. The company’s market cap of Rs 129.92 crore is far below the industry median of Rs 704.59 crore and dramatically under the average of Rs 13,873.11 crore, with the sector spanning from Rs 3.8 crore to Rs 4,41,957.5 crore. On Univest, that positions Godavari Drugs as a much smaller player in a large and varied listed industry.
Peer Comparison
| Company | Symbol | Market Cap (Cr) | P/E | P/B | ROE (%) | ROCE (%) |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries | SUNPHARMA | 4,41,957.5 | 36.54 | 5.11 | 14.85 | 19.11 |
| Divi's Laboratories | DIVISLAB | 2,47,576 | 84.64 | 14.02 | 16.19 | 21.51 |
| Torrent Pharmaceuticals | TORNTPHARM | 1,89,233.01 | 86.76 | 21.08 | 26.76 | 19.27 |
| Zydus Lifesciences | ZYDUSLIFE | 1,11,670.55 | 24.74 | 4.14 | 19.69 | 21.39 |
| Cipla | CIPLA | 1,10,272.68 | 32.72 | 3.14 | 11.83 | 16 |
Godavari Drugs looks inexpensive on some valuation measures relative to large pharmaceutical peers, but it also trails most of them on profitability and scale. That is the main conclusion from comparing its P/E, P/B, ROE, ROCE and market capitalisation with the supplied peer group.
Against Sun Pharmaceutical Industries, Divi’s Laboratories, Torrent Pharmaceuticals, Zydus Lifesciences and Cipla, the size gap is immediate. Godavari Drugs has a market cap of Rs 129.92 crore, versus Rs 4,41,957.5 crore for Sun Pharma, Rs 2,47,576 crore for Divi’s, Rs 1,89,233.01 crore for Torrent, Rs 1,11,670.55 crore for Zydus and Rs 1,10,272.68 crore for Cipla. Its P/E of 31.26 is lower than Sun Pharma’s 36.54, Divi’s 84.64 and Torrent’s 86.76, close to Cipla’s 32.72, and above Zydus Lifesciences at 24.74.
On P/B, Godavari Drugs at 1.65 is below every supplied peer, including Cipla at 3.14 and Zydus at 4.14. But its ROE of 10.64% is below Sun Pharma’s 14.85%, Divi’s 16.19%, Torrent’s 26.76%, Zydus 19.69% and slightly below Cipla’s 11.83%. ROCE of 10.13% is also below all five peers, whose figures range from 16.00% to 21.51%. So the relative picture is clear: lower valuation, but also lower operating returns.
Why Investors Are Watching Godavari Drugs
- The stock fell 10.45% today from Rs 119.04 to Rs 106.60, making the price action immediately notable.
- Today’s range of Rs 115.75 to Rs 105.65 shows weakness persisted after the open.
- The P/E of 31.26 and P/B of 1.65 are below the industry median levels of 32.72 and 3.05.
- ROE of 10.64% and ROCE of 10.13% show profitability that is not yet matching stronger large-cap peers.
- As a Micro Cap in Pharmaceuticals & Drugs, the stock sits in a large 204-company industry with wide valuation dispersion.
About Godavari Drugs
Godavari Drugs is part of the Healthcare sector and operates in the Pharmaceuticals & Drugs industry. In listed-market terms, it is a Micro Cap company with a market capitalisation of Rs 129.92 crore. That places it in a highly competitive industry where the same-industry benchmark spans 204 companies, from very small businesses to some of India’s largest pharmaceutical groups.
For investors tracking Godavari Drugs Company News, the listed context matters: this is a much smaller company than peers such as Sun Pharma, Divi’s Laboratories, Torrent Pharmaceuticals, Zydus Lifesciences and Cipla. That makes company-specific valuation, profitability and price action especially important when reviewing Godavari Drugs Share News and broader market positioning on Univest.
Track Godavari Drugs Share Price on Univest
UseUnivest top decliners screener,Univest market blogsto review live stock data, top decliners and related market analysis.
On Univest, investors can track Godavari Drugs Share Price, live market moves, valuation ratios, profitability metrics, peer comparison, shareholding pattern, 52-week levels and broader market insights in one place. For anyone following Godavari Drugs Latest News or a fresh Godavari Drugs Share Price Fall, a structured dashboard helps separate one-day price action from longer-term financial context.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions
Why is Godavari Drugs Share Price falling today?
Ans. Godavari Drugs Share Price is down because the stock fell from the previous close of Rs 119.04 to Rs 106.60, a decline of Rs 12.44 or 10.45%. The supplied data confirms the fall but does not establish a company-specific.
What is Godavari Drugs Share Price Today?
Ans. Godavari Drugs Share Price Today is Rs 106.60 at the supplied update time. The stock opened at Rs 115.75, hit a high of Rs 115.75, and slipped to a low of Rs 105.65 during the session.
How much has Godavari Drugs stock fallen today?
Ans. The stock has declined by Rs 12.44 in absolute terms and 10.45% in percentage terms versus the previous close of Rs 119.04. That makes today’s move a sharp single-session decline for this Micro Cap pharmaceutical company.
Is Godavari Drugs expensive based on P/E and P/B?
Ans. Its P/E ratio is 31.26, below the same-industry median of 32.72 and average of 49.15. Its P/B ratio is 1.65, also below the industry median of 3.05 and average of 4.37, suggesting less demanding valuation multiples.
What do Godavari Drugs profitability ratios show?
Ans. ROE stands at 10.64% and ROCE at 10.13%. ROE is slightly below the industry median of 11.69% but near the 10.54% average, while ROCE is below both the 13.24% median and 13.09% average.
What does EPS, book value and dividend yield indicate for Godavari Drugs ?
Ans. EPS is Rs 3.81, showing the earnings attributable to each share. Book value per share is Rs 72.07, giving a net-worth reference. Dividend yield is 0, so the supplied data shows no current yield support.
How does Godavari Drugs compare with larger pharma peers?
Ans. Godavari Drugs has a market cap of Rs 129.92 crore, far below peers like Sun Pharma, Divi's, Torrent, Zydus and Cipla. Its P/B is lower, but its ROE and ROCE are also below all five supplied peers.
What sector does Godavari Drugs operate in?
Ans. The company operates in the Healthcare sector and the Pharmaceuticals & Drugs industry. The same-industry benchmark used here covers 204 companies, highlighting that Godavari Drugs competes in a broad and highly varied listed segment.
Is Godavari Drugs a small company by market cap?
Ans. Yes. Godavari Drugs is categorised as a Micro Cap company with a market capitalisation of Rs 129.92 crore. That is well below the industry median market cap of Rs 704.59 crore in the supplied pharmaceuticals benchmark.
